
    
      This is a non-randomized, prospective, multicenter safety and device success study. Two
      hundred fifty (250) patients are planned to be enrolled at up to 20 participating
      investigational centers in Europe and Canada. Patient participation will last for a minimum
      of 5 years. Patients will be assessed at the following intervals: baseline, hospital
      discharge, 30 days, 1 year and annually thereafter for a minimum of 5 years.
    
  